Senior GSK VP leaves to become Idorsia CCO

Simon Jose, a Brit who has spent more than 30 years in pharma, is to become chief commercial officer of Idorsia (SIX: IDIA), the research-based spin-out from Actelion following the latter’s acquisition by Johnson & Johnson (NYSE: JNJ).

Mr Jose joins the Swiss company from GlaxoSmithKline (LSE: GSK), where he was most recently senior vice president, head of global franchises and platforms.

His time with the UK pharma major also saw him serve as general manager of the UK market and as president of Stiefel, a global specialty dermatology company acquired by GSK.